OBJECTIVE: Non-invasive prenatal detection of aneuploidies can be achieved with high accuracy through sequencing of cell-free maternal plasma DNA in the maternal blood plasma. However, false positive and negative non-invasive prenatal testing (NIPT) results remain. Fetoplacental mosaicism is the main cause for false positive and false negative NIPT. We set out to develop a method to detect placental chromosomal mosaicism via genome-wide circulating cell-free maternal plasma DNA screening. METHOD: Aneuploidy detection was combined with fetal fraction determination to enable the detection of placental mosaicism. This pipeline was applied to whole genome sequencing data derived from 19 735 plasma samples. Following an abnormal NIPT, test results were validated by conventional invasive prenatal or postnatal genetic testing. RESULTS: Respectively 3.2% (5/154), 12.8% (5/39), and 13.3% (2/15) of trisomies 21, 18, and 13 were predicted and confirmed to be mosaic. The incidence of other, rare autosomal trisomies was ~0.3% (58/19,735), 45 of which were predicted to be mosaic. Twin pregnancies with discordant fetal genotypes were predicted and confirmed. CONCLUSION: This approach permits the non-invasive detection of fetal autosomal aneuploidies and identifies pregnancies with a high risk of fetoplacental mosaicism. Knowledge about the presence of chromosomal mosaicism in the placenta influences risk estimation, genetic counseling, and improves prenatal management.
OBJECTIVE: Non-invasive prenatal detection of aneuploidies can be achieved with high accuracy through sequencing of cell-free maternal plasma DNA in the maternal blood plasma. However, false positive and negative non-invasive prenatal testing (NIPT) results remain. Fetoplacental mosaicism is the main cause for false positive and false negative NIPT. We set out to develop a method to detect placental chromosomal mosaicism via genome-wide circulating cell-free maternal plasma DNA screening. METHOD: Aneuploidy detection was combined with fetal fraction determination to enable the detection of placental mosaicism. This pipeline was applied to whole genome sequencing data derived from 19 735 plasma samples. Following an abnormal NIPT, test results were validated by conventional invasive prenatal or postnatal genetic testing. RESULTS: Respectively 3.2% (5/154), 12.8% (5/39), and 13.3% (2/15) of trisomies 21, 18, and 13 were predicted and confirmed to be mosaic. The incidence of other, rare autosomal trisomies was ~0.3% (58/19,735), 45 of which were predicted to be mosaic. Twin pregnancies with discordant fetal genotypes were predicted and confirmed. CONCLUSION: This approach permits the non-invasive detection of fetal autosomal aneuploidies and identifies pregnancies with a high risk of fetoplacental mosaicism. Knowledge about the presence of chromosomal mosaicism in the placenta influences risk estimation, genetic counseling, and improves prenatal management.
Authors: Lore Lannoo; Khaila van Straaten; Jeroen Breckpot; Nathalie Brison; Luc De Catte; Eftychia Dimitriadou; Eric Legius; Hilde Peeters; Ilse Parijs; Olga Tsuiko; Leen Vancoillie; Joris Robert Vermeesch; Griet Van Buggenhout; Kris Van Den Bogaert; Kristel Van Calsteren; Koenraad Devriendt Journal: Eur J Hum Genet Date: 2022-07-27 Impact factor: 5.351
Authors: Lennart Raman; Machteld Baetens; Matthias De Smet; Annelies Dheedene; Jo Van Dorpe; Björn Menten Journal: Prenat Diagn Date: 2019-07-11 Impact factor: 3.050
Authors: Lingshan Gou; Yuan Fang; Na Wang; Man Zhang; Tianya Liu; Yi Wang; Shunan Hu; Yan Zhang; Qin Wu; Yifan Wang; Feng Suo; Maosheng Gu Journal: J Int Med Res Date: 2020-11 Impact factor: 1.671
Authors: Abel J Bronkhorst; Vida Ungerer; Frank Diehl; Philippe Anker; Yuval Dor; Michael Fleischhacker; Peter B Gahan; Lisa Hui; Stefan Holdenrieder; Alain R Thierry Journal: Hum Genet Date: 2020-10-29 Impact factor: 4.132